STOCK TITAN

So-Young Reports Unaudited Second Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

So-Young International Inc. (Nasdaq: SY) reported its Q2 2024 financial results. Total revenues were RMB407.4 million (US$56.1 million), slightly down 1.1% year-over-year but exceeding guidance. The company achieved net income of RMB18.9 million (US$2.6 million), compared to a net loss in Q2 2023. Non-GAAP net income increased to RMB22.2 million (US$3.1 million).

Key highlights include a 22.6% increase in sales of medical products and maintenance services. The company opened 14 new clinics across eight core cities. However, average mobile MAUs decreased to 1.5 million from 3.0 million in Q2 2023. For Q3 2024, So-Young expects total revenues between RMB350.0 million and RMB370.0 million, representing a 9.2% to 4.0% year-over-year decrease.

So-Young International Inc. (Nasdaq: SY) ha riportato i risultati finanziari del Q2 2024. I ricavi totali sono stati di 407,4 milioni di RMB (56,1 milioni di dollari USA), leggermente in calo dell'1,1% rispetto all'anno precedente ma superiori alle previsioni. L'azienda ha registrato , rispetto a una perdita netta nel Q2 2023. Il reddito netto Non-GAAP è aumentato a 22,2 milioni di RMB (3,1 milioni di dollari USA).

Tra i punti salienti, si evidenzia un aumento del 22,6% nelle vendite di prodotti medicali e servizi di manutenzione. L'azienda ha aperto 14 nuove cliniche in otto città principali. Tuttavia, gli MAU mobili medi sono diminuiti a 1,5 milioni da 3,0 milioni nel Q2 2023. Per il Q3 2024, So-Young prevede ricavi totali compresi tra 350,0 milioni e 370,0 milioni di RMB, rappresentando una diminuzione rispetto all'anno precedente tra il 9,2% e il 4,0%.

So-Young International Inc. (Nasdaq: SY) informó sobre sus resultados financieros del Q2 2024. Los ingresos totales fueron de 407,4 millones de RMB (56,1 millones de dólares estadounidenses), con una ligera disminución del 1,1% interanual, pero superando lo esperado. La compañía logró un ingreso neto de 18,9 millones de RMB (2,6 millones de dólares estadounidenses), en comparación con una pérdida neta en el Q2 2023. El ingreso neto No-GAAP aumentó a 22,2 millones de RMB (3,1 millones de dólares estadounidenses).

Entre los aspectos destacados se incluye un incremento del 22,6% en las ventas de productos médicos y servicios de mantenimiento. La empresa abrió 14 nuevas clínicas en ocho ciudades clave. Sin embargo, los usuarios activos mensuales móviles promedio disminuyeron a 1,5 millones desde 3,0 millones en el Q2 2023. Para el Q3 2024, So-Young espera ingresos totales entre 350,0 millones y 370,0 millones de RMB, lo que representa una disminución interanual del 9,2% al 4,0%.

So-Young International Inc. (Nasdaq: SY)가 2024년 2분기 재무 결과를 발표했습니다. 총 수익은 4억 740만 RMB (5610만 달러) 로, 전년 대비 1.1% 감소했지만 예상치를 웃돌았습니다. 회사는 순이익 1890만 RMB (260만 달러)를 기록하여 2023년 2분기의 순손실에서 벗어났습니다. Non-GAAP 기준 순이익은 2220만 RMB (310만 달러)로 증가했습니다.

주요 하이라이트로는 의료 제품 및 유지 보수 서비스 판매가 22.6% 증가한 점이 있습니다. 회사는 8개 주요 도시에서 14개의 새로운 클리닉을 개설했습니다. 그러나 평균 모바일 MAU는 2023년 2분기의 300만에서 150만으로 감소했습니다. 2024년 3분기 동안 So-Young은 총 수익을 3억 5000만에서 3억 7000만 RMB로 예상하며, 이는 전년 대비 9.2%에서 4.0% 감소하는 것입니다.

So-Young International Inc. (Nasdaq: SY) a annoncé ses résultats financiers pour le Q2 2024. Les revenus totaux se sont élevés à 407,4 millions de RMB (56,1 millions de dollars US), en légère baisse de 1,1% d'une année sur l'autre mais dépassant les prévisions. L'entreprise a réalisé un bénéfice net de 18,9 millions de RMB (2,6 millions de dollars US), par rapport à une perte nette au Q2 2023. Le bénéfice net Non-GAAP a augmenté pour atteindre 22,2 millions de RMB (3,1 millions de dollars US).

Parmi les points forts, on note une augmentation de 22,6% des ventes de produits médicaux et des services de maintenance. L'entreprise a ouvert 14 nouvelles cliniques dans huit villes clés. Cependant, le nombre moyen d'utilisateurs actifs mobiles a diminué à 1,5 million contre 3,0 millions au Q2 2023. Pour le Q3 2024, So-Young s'attend à des revenus totaux compris entre 350,0 millions et 370,0 millions de RMB, représentant une baisse d'année en année de 9,2% à 4,0%.

So-Young International Inc. (Nasdaq: SY) hat die finanziellen Ergebnisse für das Q2 2024 veröffentlicht. Die Gesamteinnahmen betrugen 407,4 Millionen RMB (56,1 Millionen USD), was einem leichten Rückgang von 1,1% im Jahresvergleich entspricht, jedoch die Prognose übertraf. Das Unternehmen erzielte einen Nettogewinn von 18,9 Millionen RMB (2,6 Millionen USD), verglichen mit einem Nettverlust im Q2 2023. Der Non-GAAP-Nettogewinn stieg auf 22,2 Millionen RMB (3,1 Millionen USD).

Zu den wichtigsten Highlights gehört ein Umsatzanstieg von 22,6% im Verkauf von medizinischen Produkten und Wartungsdiensten. Das Unternehmen eröffnete 14 neue Kliniken in acht wichtigen Städten. Die durchschnittlichen mobilen MAUs sanken jedoch von 3 Millionen im Q2 2023 auf 1,5 Millionen. Für das Q3 2024 erwartet So-Young Gesamteinnahmen zwischen 350,0 Millionen und 370,0 Millionen RMB, was einen Rückgang im Jahresvergleich von 9,2% bis 4,0% darstellt.

Positive
  • Total revenues of RMB407.4 million (US$56.1 million) exceeded guidance
  • Net income of RMB18.9 million (US$2.6 million), compared to a net loss in Q2 2023
  • Non-GAAP net income increased to RMB22.2 million (US$3.1 million)
  • 22.6% year-over-year increase in sales of medical products and maintenance services
  • Opened 14 new clinics across eight core cities
  • Beijing clinic leads in key operating metrics, including repeat customer rates and customer acquisition costs
Negative
  • Total revenues decreased 1.1% year-over-year
  • Average mobile MAUs decreased to 1.5 million from 3.0 million in Q2 2023
  • Number of medical service providers subscribing to information services decreased to 1,174 from 1,659 in Q2 2023
  • Information services and other revenues decreased 6.6% year-over-year
  • Reservation services revenues decreased 16.9% year-over-year
  • Q3 2024 revenue guidance suggests a 9.2% to 4.0% year-over-year decrease

Insights

So-Young's Q2 2024 results show a mixed performance. While total revenues decreased slightly by 1.1% year-over-year to RMB407.4 million, the company managed to swing to a net profit of RMB18.9 million, compared to a loss in the same period last year. This improvement in profitability is noteworthy.

The company's strategic shift towards medical product sales is paying off, with a significant 22.6% increase in this segment. However, the core information services revenue declined, indicating challenges in the platform business. The expansion of physical clinics could be a game-changer, but it's too early to assess its full impact.

While the company beat its revenue guidance, the Q3 outlook suggests a potential 4.0% to 9.2% year-over-year decline. This, coupled with the decrease in MAUs, raises concerns about user engagement and growth prospects. Investors should monitor these trends closely in the coming quarters.

So-Young's Q2 results reflect the ongoing transformation in China's medical aesthetics industry. The company's pivot towards a more integrated model, including product sales and physical clinics, is a strategic response to changing market dynamics. The success of the Beijing clinic in terms of repeat customer rates and customer acquisition costs is particularly promising.

However, the decline in platform subscribers and MAUs suggests a shift in how consumers and providers interact in this space. The company's focus on upstream product development and customization could be a differentiator, but it also increases competition with established beauty brands.

The medical aesthetics market in China remains volatile, with regulatory changes and consumer sentiment shifts. So-Young's diversification strategy may provide more stability, but it also increases operational complexity. The company's ability to execute across multiple business lines will be important for long-term success.

BEIJING, Aug. 23, 2024 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

  • Total revenues were RMB407.4 million (US$56.1 million[1]), compared with RMB412.1 million in the corresponding period of 2023, exceeding the high end of guidance.
  • Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with net loss attributable to So-Young International Inc. of RMB2.6 million in the same period of 2023.
  • Non-GAAP net income attributable to So-Young International Inc.[2] was RMB22.2 million (US$3.1 million), compared with non-GAAP net income attributable to So-Young International Inc. of RMB15.5 million in the same period of 2023.

Second Quarter 2024 Operational Highlights

  • Average mobile MAUs were 1.5 million, compared with 3.0 million in the second quarter of 2023.
  • Number of medical service providers subscribing to information services on So-Young's platform was 1,174, compared with 1,659 in the second quarter of 2023.
  • Total number of purchasing users through reservation services was 137.5 thousand and the aggregate value of medical aesthetic treatment transactions facilitated by So-Young's platform was RMB427.8 million.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, "Our performance during the second quarter was solid with total revenue beating guidance on the back of a significant 22.6% year-over-year increase in sales of medical products and maintenance services. This solid performance is directly attributable to our strategic initiatives and ability to capitalize on industry trends and enhance the overall vertical integration and diversification of our business. We made significant progress in expanding our chain of clinics, opening 14 in prime commercial areas across eight core cities. Notably, our Beijing clinic continues to lead the industry in key operating metrics, including repeat customer rates and customer acquisition costs. We plan to swiftly replicate this proven model in other cities to further expand our offline footprint. Leveraging the reputational strength of our brand and extensive consumer behavior data, we have built a solid foundation to drive upstream product development and customization. Product sales continue to grow rapidly with a strong and diversified pipeline currently in development with our partners. Moving forward, we will continue to explore opportunities across the upstream, midstream and downstream sectors, solve industry pain points, and lead the industry towards a new era of quality medical aesthetics."

Mr. Hui Zhao, Chief Financial Officer of So-Young, added, "Growth during the quarter was fueled by the progress we made in integrating our platform across the medical aesthetic value chain. This not only promotes the high-quality and sustainable development of the industry, but also further strengthens our market position. As we accelerate the development of our new businesses, we will continue to prudently manage costs and enhance operational efficiency. We are confident that these strategic initiatives will continue to drive sustainable growth and enhance shareholder value over the long-term."

[1] This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.2672 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 28, 2024.

[2] Non-GAAP net income/(loss) attributable to So-Young International Inc. is defined as net income/(loss) attributable to So-Young International Inc. excluding share-based compensation expenses attributable to So-Young International Inc. See "Reconciliation of GAAP and Non-GAAP Results" at the end of this press release.

Second Quarter 2024 Financial Results     

Revenues

Total revenues were RMB407.4 million (US$56.1 million), a decrease of 1.1% from RMB412.1 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.

  • Information services and other revenues were RMB279.2 million (US$38.4 million), a decrease of 6.6% from RMB298.9 million in the same period of 2023. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.
  • Reservation services revenues were RMB22.4 million (US$3.1 million), a decrease of 16.9% from RMB26.9 million in the same period of 2023. The decrease was primarily due to the policy change for commission rates and subsidies.
  • Sales of medical products and maintenance services were RMB105.8 million (US$14.6 million), an increase of 22.6% from RMB86.3 million in the same period of 2023, primarily due to an increase in the order volumes for cosmetic products.

Cost of Revenues

Cost of revenues was RMB155.1 million (US$21.3 million), an increase of 3.1% from RMB150.4 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with sales of cosmetic products. Cost of revenues included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with the share-based compensation expenses of RMB0.4 million in the corresponding period of 2023.

  • Cost of services and others were RMB101.9 million (US$14.0 million), a decrease of 4.4% from RMB106.5 million in the second quarter of 2023. The decrease was primarily due to a decrease in the cost of services associated with So-Young Prime.
  • Cost of medical products sold and maintenance services were RMB53.2 million (US$7.3 million), an increase of 21.3% from RMB43.9 million in the second quarter of 2023. The increase was primarily due to an increase in costs associated with the sales of cosmetic products.

Operating Expenses

Total operating expenses were RMB245.6 million (US$33.8 million), a decrease of 13.0% from RMB282.4 million in the second quarter of 2023.

  • Sales and marketing expenses were RMB132.3 million (US$18.2 million), a decrease of 4.1% from RMB137.9 million in the second quarter of 2023. The decrease was mainly due to a decrease in expenses associated with branding and user acquisition activities. Sales and marketing expenses included share-based compensation expenses of RMB0.2 million (US$0.0 million), compared with RMB0.8 million in the corresponding period of 2023.
  • General and administrative expenses were RMB70.8 million (US$9.7 million), a decrease of 23.3% from RMB92.3 million in the second quarter of 2023. The decrease was primarily due to decreases in share-based compensation expenses and professional consulting fees. General and administrative expenses included share-based compensation expenses of RMB2.0 million (US$0.3 million), compared with RMB15.5 million in the corresponding period of 2023. The decrease in share-based compensation expenses was due to the compensation costs of the restricted share units granted in 2023, which were fully recognized by the end of the first quarter of 2024.
  • Research and development expenses were RMB42.5 million (US$5.8 million), a decrease of 18.5% from RMB52.1 million in the second quarter of 2023. The decrease was primarily attributable to improvements in staff efficiency. Research and development expenses included share-based compensation expenses of RMB0.8 million (US$0.1 million), compared with RMB1.3 million in the corresponding period of 2023.

Income Tax Benefits

Income tax benefits were RMB2.6 million (US$0.4 million), compared with income tax benefits of RMB0.8 million in the same period of 2023.

Net Income/(Loss) Attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB18.9 million (US$2.6 million), compared with a net loss attributable to So-Young International Inc. of RMB2.6 million in the second quarter of 2023.

Non-GAAP Net Income Attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses attributable to So-Young International Inc., was RMB22.2 million (US$3.1 million), compared with RMB15.5 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2023.

Basic and Diluted Earnings/(Loss) per ADS

Basic and diluted earnings per ADS attributable to ordinary shareholders were RMB0.18 (US$0.02) and RMB0.18 (US$0.02), respectively, compared with basic and diluted loss per ADS attributable to ordinary shareholders of RMB0.02 and RMB0.02, respectively, in the same period of 2023.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of June 30, 2024, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB1,245.1 million (US$171.3 million), compared with RMB1,341.6 million as of December 31, 2023.

Business Outlook

For the third quarter of 2024, So-Young expects total revenues to be between RMB350.0 million (US$48.2 million) and RMB370.0 million (US$50.9 million), representing a 9.2% to 4.0% decrease from the same period in 2023. The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, as well as customer demand, which are all subject to change.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP income/(loss) from operations and non-GAAP net income/(loss) attributable to So-Young International Inc. by excluding share-based compensation expenses from income/(loss) from operations and net income/(loss) attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company's operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company's core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future. All these are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company's results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company's performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young's management will hold an earnings conference call on Friday, August 23, 2024, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Dial-in details for the earnings conference call are as follows:

International:

+1-412-902-4272

Mainland China:

4001-201203

US:

+1-888-346-8982

Hong Kong:

+852-301-84992

Passcode:

So-Young International Inc.

A telephone replay will be available two hours after the conclusion of the conference call through 23:59 U.S. Eastern Time, August 30, 2024. The dial-in details are:

International:

+1-412-317-0088

US:

+1-877-344-7529

Passcode: 

3725692

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young's strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young's strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young's beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young's strategies; So-Young's future business development, financial condition and results of operations; So-Young's ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young's revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com 

Christensen

In China
Ms. Dee Wang
Phone: +86-10-5900-1548
E-mail: dee.wang@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: linda.bergkamp@christensencomms.com 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)



As of


December 31,


June 30,


June 30,

2023

2024

2024


RMB


RMB


US$

Assets






Current assets:






Cash and cash equivalents

426,119


456,927


62,875

Restricted cash and term deposits

14,695


83,224


11,452

Trade receivables

57,219


81,585


11,226

Inventories

118,924


143,374


19,729

Receivables from online payment platforms

23,158


20,819


2,865

Amounts due from related parties

9,212


10,292


1,416

Term deposits and short-term investments

900,823


704,979


97,008

Prepayment and other current assets

171,774


237,267


32,649

Total current assets

1,721,924


1,738,467


239,220

Non-current assets:






Long-term investments

261,016


278,546


38,329

Intangible assets

145,253


133,104


18,316

Goodwill

540,693


540,693


74,402

Property and equipment, net

116,782


137,162


18,874

Deferred tax assets

78,034


80,626


11,095

Operating lease right-of-use assets

118,408


139,885


19,249

Other non-current assets

232,455


183,546


25,257

Total non-current assets

1,492,641


1,493,562


205,522

Total assets

3,214,565


3,232,029


444,742







Liabilities






Current liabilities:






Short-term borrowings

29,825


39,713


5,465

Taxes payable

56,894


57,567


7,921

Contract liabilities

103,374


95,656


13,163

Salary and welfare payables

86,290


79,716


10,969

Amounts due to related parties

388


138


19

Accrued expenses and other current
liabilities

233,913


249,175


34,287

Operating lease liabilities-current

29,739


27,482


3,782

Total current liabilities

540,423


549,447


75,606

Non-current liabilities:






Operating lease liabilities-non current

86,210


114,478


15,753

Deferred tax liabilities

25,082


21,342


2,937

Other non-current liabilities

1,536


1,610


222

Total non-current liabilities

112,828


137,430


18,912

Total liabilities

653,251


686,877


94,518













Shareholders' equity:






Treasury stock

(358,453)


(365,451)


(50,288)

Class A ordinary shares (US$0.0005 par value; 750,000,000
     shares authorized as of December 31, 2023 and June 30,
     2024; 73,688,044 and 63,422,436 shares issued and
     outstanding as of December 31, 2023, 77,387,894 and
     66,469,129 shares issued and outstanding as of June 30,
     2024, respectively)

238


251


35

Class B ordinary shares (US$ 0.0005 par value; 20,000,000
     shares authorized as of December 31, 2023 and June 30,
     2024; 12,000,000 shares issued and outstanding as of
     December 31, 2023 and June 30, 2024)

37


37


5

Additional paid-in capital

3,080,433


3,065,650


421,847

Statutory reserves

33,855


33,855


4,659

Accumulated deficit

(330,166)


(332,465)


(45,749)

Accumulated other comprehensive income

18,185


23,934


3,293

Total So-Young International Inc. shareholders' equity

2,444,129


2,425,811


333,802

Non-controlling interests

117,185


119,341


16,422

Total shareholders' equity

2,561,314


2,545,152


350,224

Total liabilities and shareholders' equity

3,214,565


3,232,029


444,742

 

 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)



For the Three Months Ended


For the Six Months Ended


June 30,
2023


June 30,
2024


June 30,
2024


June 30,
2023


June 30,
2024


June 30,
2024



RMB


RMB


US$


RMB


RMB


US$















Revenues:













Information services and others

298,879


279,216


38,421


509,163


487,964


67,146


Reservation services

26,903


22,356


3,076


56,584


45,420


6,250


Sales of medical products and maintenance services

86,284


105,808


14,560


156,422


192,278


26,458


Total revenues

412,066


407,380


56,057


722,169


725,662


99,854


Cost of revenues:













Cost of services and others

(106,519)


(101,853)


(14,015)


(188,019)


(176,075)


(24,229)


Cost of medical products sold and maintenance services

(43,859)


(53,198)


(7,320)


(76,080)


(96,291)


(13,250)


Total cost of revenues

(150,378)


(155,051)


(21,335)


(264,099)


(272,366)


(37,479)


Gross profit

261,688


252,329


34,722


458,070


453,296


62,375


Operating expenses:













Sales and marketing expenses

(137,921)


(132,308)


(18,206)


(250,432)


(245,564)


(33,791)


General and administrative expenses

(92,341)


(70,799)


(9,742)


(153,855)


(155,752)


(21,432)


Research and development expenses

(52,141)


(42,498)


(5,848)


(107,934)


(82,089)


(11,296)


Total operating expenses

(282,403)


(245,605)


(33,796)


(512,221)


(483,405)


(66,519)


(Loss)/Income from operations

(20,715)


6,724


926


(54,151)


(30,109)


(4,144)


Other income/(expenses):













Investment income, net

3,370


788


108


10,222


2,887


397


Interest income, net

13,966


11,718


1,612


25,893


24,031


3,307


Exchange (losses)/gains

(1,579)


16


2


(1,154)


410


56


Share of losses of equity method investee

(3,699)


(3,733)


(514)


(6,870)


(7,729)


(1,064)


Others, net

6,562


2,039


281


8,587


5,319


732


(Loss)/Income before tax

(2,095)


17,552


2,415


(17,473)


(5,191)


(716)


Income tax benefits

785


2,571


354


5,049


5,128


706


Net (loss)/income

(1,310)


20,123


2,769


(12,424)


(63)


(10)


Net income attributable to noncontrolling interests

(1,268)


(1,182)


(163)


(2,102)


(2,236)


(308)


Net (loss)/income attributable to So-Young International Inc.

(2,578)


18,941


2,606


(14,526)


(2,299)


(318)


 

 

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Continued)

(Amounts in thousands, except for share and per share data)



For the Three Months Ended


For the Six Months Ended


June 30,
2023


June 30,
2024


June 30,
2024


June 30,
2023


June 30,
2024


June 30,
2024


RMB


RMB


US$


RMB


RMB


US$













Net (loss)/earnings per ordinary share












Net (loss)/earnings per ordinary share attributable to ordinary shareholder -
basic

(0.03)


0.24


0.03


(0.18)


(0.03)


(0.00)

Net (loss)/earnings per ordinary share attributable to ordinary shareholder -
     diluted

(0.03)


0.24


0.03


(0.18)


(0.03)


(0.00)

Net (loss)/earnings per ADS attributable to ordinary shareholders - basic (13
     ADS represents 10 Class A ordinary shares)

(0.02)


0.18


0.02


(0.14)


(0.02)


(0.00)

Net (loss)/earnings per ADS attributable to ordinary shareholders - diluted (13
     ADS represents 10 Class A ordinary shares)

(0.02)


0.18


0.02


(0.14)


(0.02)


(0.00)

Weighted average number of ordinary shares used in computing earnings/(loss)
     per share, basic*

77,310,426


79,586,926


79,586,926


78,580,369


79,569,190


79,569,190

Weighted average number of ordinary shares used in computing earnings/(loss)
     per share, diluted*

77,310,426


79,899,412


79,899,412


78,580,369


79,569,190


79,569,190













Share-based compensation expenses included in:












Cost of services and others

(412)


(229)


(32)


(1,217)


(174)


(24)

Sales and marketing expenses

(823)


(184)


(25)


(2,317)


(237)


(33)

General and administrative expenses

(15,546)


(2,015)


(277)


(21,564)


(26,468)


(3,642)

Research and development expenses

(1,305)


(817)


(112)


(2,182)


(1,660)


(228)


* Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

 

 

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)



For the Three Months Ended


For the Six Months Ended



June 30,

2023


June 30,

2024


June 30,
2024


June 30,
2023


June 30,
2024


June 30,
2024



RMB


RMB


US$


RMB


RMB


US$















GAAP (loss)/income from operations

(20,715)


6,724


926


(54,151)


(30,109)


(4,144)


Add back: Share-based compensation expenses

18,086


3,245


446


27,280


28,539


3,927


Non-GAAP (loss)/income from operations

(2,629)


9,969


1,372


(26,871)


(1,570)


(217)




























GAAP net (loss)/income attributable to So-Young International Inc.

(2,578)


18,941


2,606


(14,526)


(2,299)


(318)


Add back: Share-based compensation expenses

18,086


3,245


446


27,280


28,539


3,927


Non-GAAP net income attributable to So-Young International Inc.

15,508


22,186


3,052


12,754


26,240


3,609


 

 

Cision View original content:https://www.prnewswire.com/news-releases/so-young-reports-unaudited-second-quarter-2024-financial-results-302229399.html

SOURCE So-Young International Inc.

FAQ

What were So-Young's (SY) total revenues in Q2 2024?

So-Young's total revenues in Q2 2024 were RMB407.4 million (US$56.1 million), slightly down 1.1% year-over-year but exceeding the company's guidance.

How did So-Young's (SY) net income change in Q2 2024 compared to Q2 2023?

So-Young reported net income of RMB18.9 million (US$2.6 million) in Q2 2024, compared to a net loss of RMB2.6 million in Q2 2023, showing a significant improvement in profitability.

What was the growth rate of So-Young's (SY) medical products and maintenance services sales in Q2 2024?

So-Young's sales of medical products and maintenance services increased by 22.6% year-over-year in Q2 2024, reaching RMB105.8 million (US$14.6 million).

How many new clinics did So-Young (SY) open in Q2 2024?

So-Young opened 14 new clinics across eight core cities during Q2 2024, expanding its offline footprint.

What is So-Young's (SY) revenue guidance for Q3 2024?

For Q3 2024, So-Young expects total revenues to be between RMB350.0 million (US$48.2 million) and RMB370.0 million (US$50.9 million), representing a 9.2% to 4.0% decrease from the same period in 2023.

So-Young International Inc. American Depository Shares

NASDAQ:SY

SY Rankings

SY Latest News

SY Stock Data

86.71M
66.47M
16.02%
25.25%
0.02%
Health Information Services
Healthcare
Link
United States of America
Beijing